Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

Rhea-AI Summary

Aldeyra Therapeutics, a biotechnology company focused on immune-modulating therapies for ocular and systemic diseases, announced participation in two upcoming investor conferences. President and CEO Todd C. Brady will present at Citi's 16th Annual BioPharma Virtual Conference on September 9, 2021, at 8:50 a.m. ET, discussing next-generation retinal therapeutics. Additionally, he will be featured at H.C. Wainwright's 23rd Annual Global Investment Conference on September 13, 2021, beginning at 7:00 a.m. ET. Archived versions of these events will be available on the company's website for 90 days.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences:

• Citi’s 16th Annual BioPharma Virtual Conference
  Date: Thursday, September 9, 2021
  Time: 8:50 a.m. ET

  Panel: Eyes on the Prize - Next Generation Retinal Therapeutics

• H.C. Wainwright 23rd Annual Global Investment Conference
  Date: Monday, September 13, 2021
  Time: Available On-Demand Beginning at 7:00 a.m. ET
  Format: Analyst-Hosted Fireside Conversation

To view these events, please visit the Investors & Media page of the company’s website. After the presentations, the events will remain archived on the website for 90 days.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the company’s lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005445/en/

Corporate:

Joshua Reed

Aldeyra Therapeutics, Inc.

Tel: 781-761-4904 ext. 218

jreed@aldeyra.com

Investors & Media:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: 617-542-5300

ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.

FAQ

What is the date and time for Aldeyra's presentation at the Citi BioPharma Conference?

Aldeyra's presentation at Citi's 16th Annual BioPharma Virtual Conference is scheduled for September 9, 2021, at 8:50 a.m. ET.

When will Todd C. Brady speak at the H.C. Wainwright Global Investment Conference?

Todd C. Brady will participate in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, available on-demand starting at 7:00 a.m. ET.

How can I access recordings of Aldeyra's conference presentations?

Recordings of Aldeyra's conference presentations will be archived on the company's website for 90 days after the events.

What are the main focuses of Aldeyra's product candidates?

Aldeyra's lead product candidates, reproxalap and ADX-629, focus on treating ocular and systemic diseases by targeting RASP mediators of inflammation.

What is the stock symbol for Aldeyra Therapeutics?

The stock symbol for Aldeyra Therapeutics is ALDX.